1. Pink Sheet
  2. >>Geography
  3. >>Europe

EudraCT Vs CTIS: How EU Trial Submissions Fared In Run Up To Mandatory Requirements

 
• By Vibha Sharma

The European Medicines Agency has published the latest data on the EU clinical trials environment showing how sponsors chose to submit trial applications just ahead of the crucial 31 January 2023 deadline, when the use of the new clinical trials portal became mandatory.

Clinical trial
CTIS has ushered in major changes to the Submission, Evaluation and Conduct of clinical trials in the EU • Source: Alamy

There was a sharp rise in EU clinical trial applications (CTAs) through the EudraCT system just before the doors closed on this old CT portal on 31 January 2023, when the use of the new EU Clinical Trials Information System (CTIS) became mandatory for all initial studies.

As per latest data published by the European Medicines Agency on the EU CT environment, the number of CTAs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.